Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript

22d ago, source: Hosted on MSN

Aptose Biosciences Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Jonathan and I will ...

Aptose Biosciences Inc APTO

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

APS:CA Aptose Biosciences Inc.

14d ago, source: Seeking Alpha

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

Closing Bell: Aptose Biosciences Inc down on Monday (APS)

3d ago, source:

Detailed price information for Aptose Biosciences Inc (APS-T) from The Globe and Mail including charting and trades.

Aptose Reports Results for the Fourth Quarter and Full Year 2023

23d ago, source: Business Insider

SAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

22d ago, source: Seeking Alpha

My name is Jonathan and I will be your conference operator today. I would like to welcome everyone to Aptose Biosciences Conference Call for the Fourth Quarter and Year Ended December 31 ...

Aptose Biosciences Inc APTO

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023

23d ago, source: Finanznachrichten

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic ...

Aptose Biosciences Inc.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...